Payment overview · 2025
General Payments
$113.62
6 reported records · 5 companies
Healthcare provider profile · identity verified
Jennifer Meyer, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HOUSTON, TX · NPI 1295712768
Verified facts
What the public records show
CMS Open Payments records show Jennifer Meyer, MD received $113.62 in general payments during 2025 across 6 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 27.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $31.02 | 27.3% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $24.48 | 21.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $22.97 | 20.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $20.42 | 18.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.73 | 13.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $113.62 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $31.02 | 2 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $24.48 | 1 | 2025 |
Source payment records
|
|||||
| KEYTRUDA QLEX Normalized: keytruda qlex |
Biological | Merck Sharp & Dohme LLC | $24.48 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.97 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $20.42 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
129 | 37 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 483 | 125 |
| Levothyroxine Sodium | Levothyroxine Sodium | 461 | 126 |
| Atorvastatin Calcium | Atorvastatin Calcium | 375 | 105 |
| Amlodipine Besylate | Amlodipine Besylate | 246 | 68 |
| Pantoprazole Sodium | Pantoprazole Sodium | 158 | 44 |
| Gabapentin | Gabapentin | 151 | 39 |
| Lisinopril | Lisinopril | 138 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 135 | 31 |
| Synthroid | Levothyroxine Sodium | 129 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 126 | 42 |
| Zolpidem Tartrate | Zolpidem Tartrate | 118 | 32 |
| Alendronate Sodium | Alendronate Sodium | 114 | 39 |
| Ezetimibe | Ezetimibe | 102 | 30 |
| Methylprednisolone | Methylprednisolone | 101 | 81 |
| Hydrochlorothiazide | Hydrochlorothiazide | 100 | 26 |
| Metformin Hcl | Metformin Hcl | 95 | 27 |
| Famotidine | Famotidine | 94 | 26 |
| Trazodone Hcl | Trazodone Hcl | 91 | 25 |
| Valsartan | Valsartan | 88 | 23 |
| Losartan Potassium | Losartan Potassium | 84 | 26 |
| Furosemide | Furosemide | 82 | 27 |
| Alprazolam | Alprazolam | 80 | 24 |
| Estradiol | Estradiol | 80 | 23 |
| Azithromycin | Azithromycin | 79 | 62 |
| Tramadol Hcl | Tramadol Hcl | 76 | 27 |
| Meloxicam | Meloxicam | 70 | 23 |
| Montelukast Sodium | Montelukast Sodium | 67 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 64 | 17 |
| Bupropion Xl | Bupropion Hcl | 62 | 19 |
| Clonazepam | Clonazepam | 62 | 20 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 62 | 45 |
| Omeprazole | Omeprazole | 62 | 13 |
| Prednisone | Prednisone | 60 | 21 |
| Valacyclovir | Valacyclovir Hcl | 60 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 56 | 16 |
| Ozempic | Semaglutide | 53 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 53 | 13 |
| Eliquis | Apixaban | 52 | 11 |
| Buspirone Hcl | Buspirone Hcl | 51 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 49 | 20 |
| Januvia | Sitagliptin Phosphate | 48 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 48 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 45 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 45 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 44 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 43 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 43 | 12 |
| Simvastatin | Simvastatin | 43 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 42 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 41 | 40 |
| Spironolactone | Spironolactone | 41 | 13 |
| Clonidine Hcl | Clonidine Hcl | 37 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 36 | 16 |
| Potassium Chloride | Potassium Chloride | 36 | 13 |
| Allopurinol | Allopurinol | 35 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 32 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 32 | suppressed |
| Carvedilol | Carvedilol | 30 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 30 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 30 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 29 | suppressed |
| Ramipril | Ramipril | 28 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 24 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 24 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 23 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Jardiance | Empagliflozin | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Fluconazole | Fluconazole | 21 | 13 |
| Nystatin | Nystatin | 21 | 16 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 18 |
| Pregabalin | Pregabalin | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Premarin | Estrogens, Conjugated | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 16 |
| Lorazepam | Lorazepam | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Levoxyl | Levothyroxine Sodium | 17 | suppressed |
| Methimazole | Methimazole | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 13 |
| Mupirocin | Mupirocin | 16 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 14 |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Zolmitriptan | Zolmitriptan | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Minoxidil | Minoxidil | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $113.62 · 6 records | Bayer Healthcare Pharmaceuticals Inc. | AIRSUPRA, KEYTRUDA, KEYTRUDA QLEX, Kerendia, LINZESS, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error